Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VECTORS: Treat-to-Target Transmural Healing in Moderately to Severely Active Crohn’s Disease
2023-509096-16-00Phase 4Authorised
- Sponsor
- Alimentiv Inc.
- Start
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 4, randomised trial of vedolizumab, infliximab, adalimumab, ustekinumab, risankizumab and 3 more in Crohn's disease (2 arms), sponsored by Alimentiv Inc. Primary endpoint: Corticosteroid-free endoscopic remission at Week 48. Planned start Jul 2024; status: authorised.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-509096-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509096-16-00.